PRESS RELEASE 2024
-
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal assures diversity of supply to meet future long-term plans for expanded availability of the gene therapy Two additional...
-
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
Expanded clinical trial program with ADSTILADRIN starts up in the United States Current clinical trial program of five multi-year studies to evaluate ADSTILADRIN demonstrate Ferring’s commitment to improve outcomes for patients across the spectrum of urothelial cancers Research will enlarge the b...
-
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 in a registrational Phase 3 clinical trial An integrated safety analysis showed SI-6603 was well tolerated and could offer a potential treatment option for pain relief from Lum...
-
Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Two Patient Cohorts
Results of a Phase 3 study show durable complete response in evaluation of high-grade recurrence-free survival, cystectomy-free survival, and overall survival in patients with CIS ± Ta/T1 (primary analysis) and high-grade Ta/T1 without CIS (secondary analysis) Among the 53% of patients with BCG-u...
-
Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting
Ferring presenting design and methodology for the ABLE-41 Real-World Evidence study at this week’s 20th Annual ASCO Genitourinary Cancers Symposium in San Francisco Study evaluating effectiveness, overall experiences, patterns of use, and safety of the first and only FDA-approved intravesical gen...
-
Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
Patients with high-risk, non-muscle invasive bladder cancer now have greater access to the first and only FDA-approved intravesical gene therapy With full supply of ADSTILADRIN ahead of schedule, Ferring ends the temporary ADSTILADRIN Early Experience Program Enrollment in ABLE-41 U.S. Real-World...